Avenue Therapeutics to Present at March Investor Conferences
05 mars 2018 08h00 HE
|
Avenue Therapeutics
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Highlights
01 mars 2018 07h30 HE
|
Avenue Therapeutics
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO & Investor Conference
06 févr. 2018 08h30 HE
|
Avenue Therapeutics
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the Management of Postoperative Pain
02 janv. 2018 08h00 HE
|
Avenue Therapeutics
NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
09 nov. 2017 07h30 HE
|
Avenue Therapeutics
NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced financial results and recent corporate...
Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain
27 sept. 2017 08h00 HE
|
Avenue Therapeutics
NEW YORK, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that the first patient has been dosed in...
Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate Controller (principal financial and accounting officer)
15 août 2017 08h00 HE
|
Avenue Therapeutics
NEW YORK, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced the appointment of Joseph Vazzano as Vice...
Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
11 août 2017 07h30 HE
|
Avenue Therapeutics
NEW YORK, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced financial results and recent corporate...
Avenue Therapeutics Completes Initial Public Offering
30 juin 2017 11h30 HE
|
Avenue Therapeutics
NEW YORK, June 30, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech, Inc. (NASDAQ:FBIO) company, announced today that it has completed its initial...
Avenue Therapeutics Prices Initial Public Offering of $33,000,000 of Common Stock
26 juin 2017 19h30 HE
|
Avenue Therapeutics
NEW YORK, June 26, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech, Inc. (NASDAQ:FBIO) company, announced today the pricing of its initial public offering of...